Recent studies have shown that patients whose bladder cancer exhibit overexpression of RB protein as measured by immunohistochemical analysis do equally poorly as those with loss of RB function. We hypothesized that loss of p16 protein function could be related to RB overexpression, since p16 can induce transcriptional downregulation of RB and its loss may lead to aberrant RB regulation. Conversely, loss of RB function has been associated with high p16 protein expression in several other tumor types. In the present study RB negative bladder tumors also exhibited strong nuclear p16 staining while each tumor with strong, homogeneous RB nuclear staining were p16 negative, supporting our hypothesis. To expand on these immunohistochemical studies additional cases were selected in which the status of the p16 encoding gene had been determined at the molecular level. Absent p16 and high RB protein expression was found in the tumors having loss of heterozygosity within 9p21 and a structural change (mutation or deletion) of the remaining p16 encoding gene allele, con®rming the staining results. These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.
Introduction
Inactivation of the RB gene is a common event in bladder cancer (Horowitz et al., 1990; Ishikawa et al., 1991; Xu et al., 1993) and is seen more frequently in higher grade and invasive stage tumors (Xu et al., 1993) . Moreover, loss of RB function has been associated with progression to invasive disease and decreased survival (Cordon-Cardo et al., 1992; Logothetis et al., 1992) . In addition it was recently found that patients whose bladder cancer showed overexpression of RB protein by immunohistochemical (IHC) analysis had an increased rate of progression and decreased survival rate comparable to those patients with tumors exhibiting no RB protein expression (Cote et al., 1998; Grossman et al., 1998) . These ®ndings suggest that bladder tumors with a strong, homogeneous staining pattern may re¯ect abnormal RB status resulting in a similar pathological eect as those tumors with absent RB protein expression. In the present study we sought to determine the reason for the strong homogeneous RB staining pattern observed in some bladder tumors which may as well be relevant to other tumor types.
Direct evidence to support a role for p16 as a modulator of overall RB expression levels recently has been reported (Fang et al., 1998) . Wild-type p16 was transferred into ovarian cancer cell lines as well as a bladder cancer cell line, all of which were p16-negative and RB-positive. These cell lines had an increased RB expression at both the protein and mRNA level compared to cell lines from the same tumor types that were p16 positive. Moreover, when p16 was reexpressed in these cells a marked decrease in the level of total RB protein was seen resulting primarily from the disappearance of the hyperphosphorylated RB forms. This RB change was shown to be secondary to a p16 induced decrease in transcription of the RB gene.
Conversely, extending the interrelationship between RB and p16, it also has been found that loss of RB function is inversely correlated with p16 expression. For many tumor types RB negative cells show increased p16 protein levels (e.g. Okamoto et al., 1994; Otterson et al., 1994; Kratzke et al., 1996; Shapiro et al., 1995; Yeager et al., 1995; Sakaguchi et al., 1996) . This p16 overexpression is likely caused by the absence of RB to downregulate p16 protein production, although p16 overexpression has no eect in the absence of RB (Lukas et al., 1995) .
To test our hypothesis that overexpression of RB was related to loss of p16 function, bladder tumors in which both the transurethral biopsy (TURB) and cystectomy specimen could be obtained were scored for their RB and p16 status by IHC analysis. Additional tumors that had been examined for loss of heterozygosity (LOH) at 9p21 (the location of the p16 encoding gene) and for the presence or absence of homozygous deletions or mutations in the remaining p16 encoding gene allele were also studied for both RB and p16 protein expression to con®rm the accuracy of our staining results.
Results

Status of RB and p16 determined by IHC analysis
We have previously demonstrated that there is a heterogeneous nuclear RB staining pattern, ranging from strongly to weakly positive tumor cells as well as those which were negatively stained in cancers having no apparent loss of RB function and that such heterogeneity re¯ected in part cell cycle dierences in RB protein expression . In each section numerous endothelial and other cell types also showed heterogeneous nuclear RB staining as internal controls, including normal urothelium in the case of bladder specimens. In contrast, we found that often only a small fraction of normal cells showed p16 nuclear staining on each slide as internal positive controls, which appeared mostly to be reactive ®broblasts. Nevertheless, there were sucient p16 positive normal cells in each section to allow the p16 protein status in the tumors to be determined. Of particular importance also was the fact that hyperplastic or dysplastic urothelium as well as most super®cial Ta lesions showed a normal heterogeneous p16 staining pattern, Figure 1 Typical cases of RB and p16 staining in bladder tumors. (a) and (b) show the heterogeneous staining for both RB and p16, respectively which is considered normal. A tumor which is RB negative (c) and homogeneously strong staining for p16 (d) is shown next. The arrow in (c) is an example of a normal RB positive cell used as an internal positive control for RB negative cases. Finally, a tumor with homogeneously strong RB (e) and negative p16 (f) staining is shown. The arrows in (f) illustrate the presence of normal p16 positive cells necessary to be seen in p16 negative tumors although the level of p16 protein expression in normal urothelium was below that detected by IHC analysis. Therefore, IHC staining appeared to be an accurate and sensitive method to examine the p16 status in a given tumor.
In the initial cohort studied we observed that bladder tumors with heterogeneous RB protein staining also had a heterogeneous p16 staining pattern (Figure 1a and b, respectively) . Moreover, directly related to our hypothesis, tumors with strong, homogeneous RB nuclear staining consistently showed no p16 staining (Figure 1e and f, respectively) and were therefore considered to have aberrant p16 function. Finally, RB negative tumors showed strong p16 staining (Figure 1c and d, respectively). Cytoplasmic p16 staining was common in the presence of nuclear staining particularly in those tumors with strong p16 expression (e.g. Figure 1d ), but was not found in p16 negative tumors, suggesting that this staining was p16 speci®c. However, only nuclear p16 staining was used to score p16 status by IHC.
The relationship between RB and p16 staining patterns in the TURB and corresponding cystectomy specimens is shown in Table 1 . There was no discrepancy between the scoring of RB or p16 status between the TURBs and the same tumors obtained at cystectomy. These results attest to the consistency of the IHC scoring, the inverse relationship between RB and p16 staining, and the heterogeneous staining pattern seen for both RB and p16 in tumors which apparently had no functional loss of either protein.
Relationship between LOH at 9p21 and/or homozygous deletions/mutations within the MTS-1 gene and p16 or RB status as determined by IHC Additional tumors were examined in which it had been determined if LOH at 9p21 (the locus of the MTS-1/ INK4a gene encoding for p16) and/or structural changes in the MTS-1 gene itself had occurred. The relationship of 9p21 LOH, MTS-1 genetic alteration, and p16/RB nuclear protein status is summarized in Table 2 . The cases used for this study were selected from a larger cohort of over 100 bladder tumors. They were chosen to con®rm the accuracy of the previous IHC analysis. These cases do not re¯ect the overall frequency of MTS-1 speci®c alterations in bladder tumors, which are less than that seen for the selected tumors in Table 2 . Six cases had no LOH or MTS-1 abnormality and showed a heterogeneous p16 and RB staining pattern. Ten other cases showed LOH at 9p21 but no MTS-1 change could be demonstrated in the remaining allele. These tumors also had heterogeneous p16 staining, implying that the remaining MTS-1 allele was normal and that the structural analysis of the MTS-1 gene was quite accurate. One additional case with LOH at 9p21 and no MTS-1 structural alteration had strong homogeneous rather than heterogeneous p16 staining but was, as expected, RB negative. Another tumor showed both heterogeneous p16 and RB staining, although it had a mutation within MTS-1. However, no LOH of 9p21 was present, suggesting that the other MST-1 allele was normal. Finally, three bladder cancers had LOH within 9p21 as well as an MTS-1 mutation of the remaining allele and one tumor showed LOH of 9p21 with a homozygous deletion of the other MTS-1 allele ( Figure 2 ). All four of these latter tumors had absent p16 staining in their malignant cells, as well as strong homogeneous RB staining, further supporting the accuracy of IHC analysis to determine the status of p16 and to provide genetic veri®cation of the correlation between loss of p16 function and overexpresssion of RB. There was also no correlation between dierences in RB patterns and cell cycle status as measured by Ki-67 staining (data not shown).
Discussion
The results support our hypothesis that loss of p16 function is directly related to the overexpression of RB found in certain bladder cancers and this may extend to other tumor types as well. These and other ®ndings reported in the present study have both clinical and basic importance. Before discussing them, however, it should be mentioned that the MST-1/INK4a locus also has recently been shown to encode for a second tumor suppressor protein, namely p19-ARF, which uses the same MST-1/INK4a second exon with an alternate reading frame as is utilized to produce p16 (Quelle et al., 1995) . Moreover, as both gene products are often mutated in the same tumor, one might question if p19-ARF loss could also be related to the RB overexpression seen in p16 negative tumors. It would appear that such a relationship does not exist, since p19-ARF inhibits cell cycle progression through a p53 rather than an RB pathway by promoting MDM2 degradation and stabilizing wild-type p53 (Pomerantz et al., 1998 , Zhang et al., 1998 . Nevertheless, the simultaneous loss of both p16 and p19-ARF could be a major factor in the overall prognosis of certain individuals with bladder cancer who do not have additional mutations in p53 which should become evident from the discussions below. It was two recent clinical reports which provided the impetus for our current studies. As stated previously, these latter two studies used the same criteria and methodology to determine the RB status in bladder tumors as was utilized in our present report. It was found that patients whose tumor overexpressed RB protein had a similar increased progression rate and a decreased overall survival as individuals whose tumor was RB negative (Cote et al., 1998; Grossman et al., 1998) . This relationship was seen for both super®cial and highly invasive tumors. Moreover, these studies documented that the clinical outcome was even considerably worse if aberrant p53 protein expression was also present in the same tumor. In this context, it might be particularly relevant in the future to determine the p19-ARF status in patients whose tumor is p16 negative without evidence of p53 alteration, since those having functional loss of p19-ARF could have a similar poor prognosis as those with p53 mutations based on the recent reports that p19-ARF functions by promoting MDM2 degradation in turn stabilizing p53. Loss of p19-ARF function might, therefore, result in the same decreased survival as seen in patients with p53 alterations.
The results from these two studies paralleled a previous report on super®cial bladder cancer showing that individuals with loss of RB function had an increased progression rate and decreased survival compared to those with a normal heterogeneous staining pattern (Cordon-Cardo et al., 1997) . Again, Figure 2 Homozygous deletions in the MTS-1 locus of case 19 (Table 2) . A map of the tested region with positions of the MTS-1 and MTS-2 exons and STS sites is shown in (a). The order is as reported (Kamb et al., 1997 ). Retention of all tested markers in a bladder tumor is seen in (b)., whereas a homozygous deletion of three markers (C18.b,C5.1 and RN3.1) is documented in (c). Con®rmation by Southern blotting of the homozygous deletions shown in (c) is illustrated in (d). N=non-tumor DNA; T=tumor DNA an even worse survival was found in patients whose tumors had both RB and p53 abnormalities. However, in this latter study only RB negative staining was used as the criterion to score a tumor as having functional RB loss, since both heterogeneously and homogeneously stained tumors were grouped together and were considered to have normal RB function. Nevertheless, despite including RB overexpressors in the normal RB group, patients with alterations in RB still showed a marked increase in progression and decrease in survival rate compared to those individuals whose tumors were scored as RB negative. Because of the similarity in the ®ndings between this study (CordonCardo et al., 1997) and the other report on super®cial tumors (Grossman et al., 1998) in which both absent and overexpression of RB was scored as abnormal, it is likely that there were few, if any, strong RB (presumably p16 negative) staining cases in the ®rst study (Cordon-Cardo et al., 1997) to be misinterpreted as having normal RB function. This is consistent with our yet unpublished observations indicating that most super®cial tumors, particularly Ta lesions, have a heterogeneous staining pattern for both p16 and RB. Documenting p16 positive internal controls for each tumor was perhaps one of the most dicult problems encountered in this study, since they in general were not frequent when compared to the usual number of RB positive controls in the same sample. It was also initially found that there was a much shorter time after the slides were prepared that optimal p16 staining could be obtained compared to that of RB staining. Therefore, slides were kept in the cold after sectioning and the staining was done within 1 ± 2 weeks after the tumor sections were cut. If this procedure was not followed, the p16 staining decreased dramatically and the chance of ®nding positive internal p16 controls was markedly diminished.
The absence of p16 protein expression in tumors having LOH at 9p21 together with either an MTS-1 deletion or a mutation generating a stop codon within the remaining allele was used to con®rm the accuracy of our p16 IHC staining. For tumors with LOH within 9p21 but no homozygous deletion or mutation in the remaining MTS-1 allele a heterogeneous p16 staining pattern was observed. We interpreted this as normal p16 expression given the absence of any structural p16 gene abnormalities and the fact that heterogeneous staining has been found in hyperplastic and dysplastic urothelium. Heterogeneous p16 staining was also associated with normal heterogeneous RB staining in these same tumors, again suggesting that both p16 and RB function were normal in these cases.
One also might speculate that the overexpression of RB protein seen in a portion of bladder tumors re¯ects the fact that the majority of the RB protein is maintained in its hyper-phosphorylated (inactive) forms which in turn results from the loss of normal p16 feedback to regulate RB production. Although direct evidence to support this concept has recently been reported (Fang et al., 1998) , other possibilities exist as the basis for the RB overexpression observed secondary to functional p16 loss which could be, in fact, more likely. This conclusion is drawn from the well documented recent report that cyclin D: Cdk4/6 complexes hypo-phosphorylate RB to their active forms rather than hyper-phosphorylate RB to their inactive forms (Ezhevski et al., 1997) . Therefore both hypo and hyper-phosphorylated RB could be present in the tumors overexpressing RB in which p16 function has been lost.
Another implication of this study is that there may be another tumor suppressor on 9p21 in addition to the MTS-1 locus involved in bladder tumorigenesis, since all the cases with LOH at 9p21 but without evidence of a MTS-1 deletion or a mutation of the remaining MTS-1 allele were p16 positive ( Table 2 ). The existence of one or more additional tumor suppressor genes on 9p21 has also been suggested by others. This possibility has been based on the fact that LOH of 9p21 is common in bladder cancers, but homozygous deletion and mutation directly eecting the MTS-1 gene is much less frequent (Cairns et al., 1994; Spruck et al., 1994; Packenham et al., 1995; Orlow et al., 1995) . Nevertheless, others have suggested not only that p16 loss of function is a common event in bladder cancer, but also that it is the major target for deletion at 9p21 in bladder cancer (Williamson et al., 1995) .
Although the cases we selected for p16 staining having LOH at 9p21 and homozygous deletion or point mutation of the remaining MTS-1 allele were con®rmed to be p16 negative by IHC analysis, an alternative mechanism for the loss of p16 protein expression in additional cases would be expected to be hypermethylation within the promoter region of the MTS-1 gene. It is well known that hypermethylation involving p16 is a frequent mechanism for loss of p16 expression in several common cancers (Merlo et al., 1995; Reed et al., 1996; Wong et al., 1997) but is substantially less frequent in bladder cancer (Spruck et al., 1994) . However, regardless of the mechanism, our data support the hypothesis that loss of p16 protein expression is associated with the overexpression of RB recently reported to have similar biological and clinical signi®cance as loss of RB expression in bladder tumors (Cote et al., 1998; Grossman et al., 1998) . Moreover, the relationship between overexpression of RB and loss of p16 function also may extend to other tumor types, particularly to those tumor types for which loss of RB function has been implicated as a key factor in their progression including osteosarcomas, ®brosarcomas and non-small cell lung carcinomas (Benedict et al., 1990) . We, in fact, believe that this will be the case and presently are examining this possibility.
Materials and methods
Tumor specimens
We examined 24 paran-embedded bladder tumors in which both the pre-cystectomy biopsies (TURB) and matched cystectomy specimens were available to study their RB and p16 status by IHC analysis. In addition, 22 tumors were selected by one of us (BC) in which the status of LOH at 9p21 as well as genetic alterations within the MTS-1 gene itself had already been determined on fresh samples. The presence of tumor tissue in the fresh tumor samples was veri®ed microscopically on hematoxylin and eosin stained sections. If necessary the portions of samples containing predominently tumor tissue were microdissected from the tissue blocks. All fresh tumor samples used for DNA extraction contained mostly (80 ± 90%) tumor tissue with minimal stromal elements.
For the latter studies in order to compare microsatillite allelic patterns in the tumors, DNA was also extracted from peripheral blood lymphocytes and/or normal tissue associated with resection specimens of each patient. Paran-embedded bladder tumor blocks were then obtained from the same 22 cases for IHC analysis. The individual scoring the RB and p16 status in these tumors (WB) had no knowledge of the LOH and MTS-1 genetic results before making the determination of the RB and p16 staining patterns.
IHC analysis and scoring
Immunohistochemical staining for RB and p16 was performed on formalin ®xed paran-embedded tissue sections. The protocol for staining RB nuclear protein has been previously described (Xu et al., 1996 , Grossman et al., 1998 . Brie¯y, after hydrogen peroxide treatment (0.3% in absolute methanol for 30 min) to block the endogenous peroxide activity, the slides were washed in glass distilled water and placed in 0.01 M sodium citrate buer (pH 6.0) for 15 min at 958C, which was followed by rinsing in distilled water and PBS. The slides were then processed for staining of RB protein using the polyclonal anti-RB antibody, RB-WL-1 (Xu et al., 1989 ) at a dilution of 1 : 628. The staining protocol for p16 was similar, except the monoclonal anti-p16 antibody, NCL-p16, clone DCS-50 (Vector Laboratories, Burlingame, CA, USA) at a 1 : 25 dilution was used. The primary antibodies were visualized using their respective ABC Elite Kits (Vector Laboratories, Burlingame, CA, USA) with 0.05% 3,3'-diamino-benzidine in Tris-HCl buer containing 0.01% Toluidine blue. In addition all cut sections were kept at 48C prior to staining. Staining was performed for p16 within 14 days after sectioning, since unlike staining for RB, which can be done at greatly extended periods after sectioning, p16 protein staining was rapidly diminished and it was often particularly dicult to ®nd p16 positive internal positive controls if the slides were not stained soon after preparation.
Tumors were considered to have a normal heterogeneous RB pattern if various intensities of RB nuclear staining were seen in malignant cells, including those with no staining (Figure 1a) . Such a normal pattern was expected because of the dierences in RB protein expression usually observed throughout the cell cycle and was not unlike the staining pattern often seen in areas of normal urethelium. Similarly, a tumor was termed heterogeneous for p16 if it had relatively weak nuclear staining with considerable dierences in nuclear intensity, including many negative cells (Figure 1b ). Tumors were scored as RB negative if no tumor cell had RB nuclear staining but contiguous RB positive normal cells were present as an internal positive control (Figure 1c ). Strong p16 staining was considered to be present if the majority of the malignant cells had intense p16 nuclear expression and p16 negative tumor cells were rare. Tumors were scored as strongly RB positive if the majority of nuclei (in general 50% or more) showed an intense RB pattern and the number of RB negative staining cells were minimal (Figure 1e ). Finally, a tumor was termed p16 negative if no malignant cells had positive staining and at least several contiguous p16 positive normal cells were present as internal controls (Figure 1f ). Some cytoplasmic p16 staining was seen in almost all p16 positive cases and was often quite prevalent in tumors with stong p16 nuclear staining (eg. Figure 1d ). This was considered to represent normal p16 staining, since none of the non-tumor cells had background cytoplasmic staining (Figure 1b and d) and thus the cytoplasmic staining found in the tumor cells appeared to be speci®c for p16.
Each section was submitted by pathology number and in general the scorer did not know which specimens were related to each other, i.e. TURB and corresponding cystectomy. In none of 22 tumors for which the molecular status of 9p21 and MST-1 had been studied did the scorer know the DNA results prior to determining the p16 and RB status by IHC.
Microsatillite analysis of 9p21
Allelic losses in the 9p21 region were tested with the marker D9S492, which is located between exons 1 and 2 of the MTS-1 gene, and¯anking markers, D9S171, D9S169, D9S270. Positions of the markers, their levels of heterozygosity and distances were obtained from the Human Genome Database version March 15, 1996 (Dib et al., 1996) . The allelic patterns of the markers were resolved on polyacrylamide gels after their ampli®cation using the polymerase chain reaction as previously described and compared between tumors and normal DNA samples of the same patient (Chaturverdi et al., 1997) . A minimum of 50% reduction in signal intensity was required to be considered evidence of LOH. Tests with the questionable results were repeated. In such cases, the densitometric measurements were performed to ensure objective reading of the data. The hybridization signal of the actin gene in normal and tumor DNA samples was used as a control. Allelic loss of 9p21 was identi®ed if at least one of the informative markers in the region showed LOH.
Alterations of MTS-1
The presence of homozygotic deletions within the MTS locus were tested using sequence-tagged site (STS) primers (1063.7, c18.b, c5.1, RN3.1, c5.3, R2.3, R2.7, and c1.b) positioned within the MTS locus as reported (Kamb et al., 1997) . The presence of homozygotic deletions in the MTS locus was con®rmed by Southern blotting. The probes used for Southern blotting represented the DNA fragments ampli®ed by the STS primers that exhibited homozygotic deletions in a given site. The probes were labeled by the random priming method and the hybridizations were carried out using standard conditions (Chaturvedi et al., 1997) . The hybridization signal was compared between tumor and non-tumor DNA samples.
Alterations with coding sequences of the MTS gene were tested by single strand conformational polymorphism (SSCP) and direct sequencing of the PCR ampli®ed gene fragments using the following primers: MTS1 (exon 1) 5' GAA GAA AGA GGA GGG GCT G 3' 5' GCG CTA CCT GAT TCC AAT TC 3' MTS1 (exon 2) 5' GGA AAT TGG AAA CTG GAA GC 3' 5' TCT GAG CTT TGG AAG CTC T 3' MTS1 (exon 3) 5' TTC TTT CTG CCC TCT GCA 3' 5' GCA GTT GTG GCC CTG TAG GA 3'
For SSCP analysis, 100 ng of genomic DNA was ampli®ed by PCR using 1 mM each of the primers, as previously described (Chaturvedi et al., 1997) . To con®rm the presence of alterations identi®ed by SSCP, direct sequencing of PCRgenerated MTS gene fragments were performed using the Sequenase PCR Product Sequencing kit (United States Biochemical Corp., Cleveland, OH, USA) according to the protocol supplied by the manufacturer.
